NANOBIOTIX to Participate in Two Upcoming Investor Conferences
May 11 2022 - 4:15PM
Business Wire
Regulatory News:
NANOBIOTIX (Euronext : NANO –– NASDAQ: NBTX – the
"Company"), a clinical-stage biotechnology company
pioneering physics-based approaches to expand treatment
possibilities for patients with cancer, today announced that
Laurent Levy, co-founder and chairman of the executive board, and
Bart Van Rhijn, chief financial officer, will participate in the
following conferences:
UBS Global Healthcare Conference
- Presentation Date: Monday, May 23rd, 2022
- Time: 10:45 AM ET
- Location: New York, New York, USA
H.C. Wainwright Global Investment Conference
- Presentation Date: Wednesday, May 25th, 2022
- Time: 8:30 AM ET
- Location: Virtual and Miami, Florida, USA
A live audio webcast of each presentation will be available on
the events page of the Investors section of the Company’s website.
A replay will be available on the Nanobiotix website within 48
hours after each event. The Company’s corporate presentation can be
downloaded here.
About NANOBIOTIX Nanobiotix is a late-stage clinical
biotechnology company pioneering disruptive, physics-based
therapeutic approaches to revolutionize treatment outcomes for
millions of patients; supported by people committed to making a
difference for humanity. The company’s philosophy is rooted in the
concept of pushing past the boundaries of what is known to expand
possibilities for human life.
Incorporated in 2003, Nanobiotix is headquartered in Paris,
France. The company also has subsidiaries in Cambridge,
Massachusetts (United States), France, Spain, and Germany.
Nanobiotix has been listed on the regulated market of Euronext
in Paris since 2012 and on the Nasdaq Global Select Market in New
York City since December 2020.
Nanobiotix is the owner of more than 30 umbrella patents
associated with three (3) nanotechnology platforms with
applications in 1) oncology; 2) bioavailability and
biodistribution; and 3) disorders of the central nervous system.
The company's resources are primarily devoted to the development of
its lead product candidate– NBTXR3 —which is the product of its
proprietary oncology platform and has already achieved market
authorization in Europe for the treatment of patients with soft
tissue sarcoma under the brand name Hensify®.
For more information about Nanobiotix, visit us at
www.nanobiotix.com or follow us on LinkedIn and Twitter.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220511005934/en/
Nanobiotix Communications Department Brandon Owens VP,
Communications +1 (617) 852-4835 contact@nanobiotix.com
Investor Relations Department Kate McNeil SVP, Investor
Relations +1 (609) 678-7388 investors@nanobiotix.com
Media Relations FR – Ulysse Communication Pierre-Louis
Germain +33 (0) 6 64 79 97 51
plgermain@ulysse-communication.com
US – Porter Novelli Caitlin Hunt +1 (781) 985-5967
Caitlin.hunt@porternovelli.com
Nanometrics (NASDAQ:NANO)
Historical Stock Chart
From Jul 2024 to Aug 2024
Nanometrics (NASDAQ:NANO)
Historical Stock Chart
From Aug 2023 to Aug 2024